Company: ZLAB
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001628280-25-008409
Chunk: 49

Company: Zai Lab Ltd
Filing Date: 2025-02-27
Form: 10-K
Item: Item 16
Chunk 49
---
 liabilities ($ in thousands):December 31,20242023Accrued payroll30,198 33,711 Accrued professional service fee5,728 7,520 Payables for purchase of property and equipment449 2,474 Accrued rebate to distributors10,839 16,926 Tax payables5,154 16,988 Other (i)6,352 5,353 Total58,720 82,972 

(i)Other primarily includes accrued travel, business-related expenses, other payables to employees, and advance payments from partners. 

14.    Loss Per Share 

The following table presents the computation of the basic and diluted net loss per share ($ in thousands, except share and per share data):Year Ended December 31,202420232022Numerator:Net loss attributable to ordinary shareholders(257,103)(334,620)(443,286)Denominator:Weighted average number of ordinary shares - basic and diluted989,477,730966,394,130958,067,140Net loss per share-basic and diluted(0.26)(0.35)(0.46)As a result of the Company’s net loss for 2024, 2023, and 2022, share options and non-vested restricted shares outstanding in the respective periods were excluded from the calculation of diluted loss per share as their inclusion would have been anti-dilutive.December 31,202420232022Share options101,015,470104,584,05091,181,420Non-vested restricted shares31,951,71031,279,60033,433,890

15.    Share-Based Compensation 

The Company has adopted equity incentive plans, pursuant to which the Company grants share options, SARs, restricted and unrestricted shares, and share units, performance awards, and other awards that are convertible into or otherwise based on ordinary shares to employees and directors of the Company as well as to certain advisors and service providers. In March 2015, the Board of Directors of the Company approved such an Equity Incentive Plan (the “2015 Plan”). In August 2017, in connection with the completion of the Company’s initial public offering on Nasdaq (the “IPO”), 

F-29

Zai Lab LimitedNotes to the Consolidated Financial StatementsFor the Years Ended December 31, 2024, 2023, and 2022

the Board of Directors approved the